UK markets close in 6 hours 28 minutes
  • FTSE 100

    7,501.31
    -5.80 (-0.08%)
     
  • FTSE 250

    20,276.99
    -21.01 (-0.10%)
     
  • AIM

    923.46
    +3.68 (+0.40%)
     
  • GBP/EUR

    1.1833
    -0.0025 (-0.21%)
     
  • GBP/USD

    1.2236
    +0.0018 (+0.15%)
     
  • BTC-GBP

    20,041.52
    +1,058.49 (+5.58%)
     
  • CMC Crypto 200

    577.30
    +46.07 (+8.67%)
     
  • S&P 500

    4,210.24
    +87.77 (+2.13%)
     
  • DOW

    33,309.51
    +535.11 (+1.63%)
     
  • CRUDE OIL

    92.13
    +0.20 (+0.22%)
     
  • GOLD FUTURES

    1,803.00
    -10.70 (-0.59%)
     
  • NIKKEI 225

    27,819.33
    -180.63 (-0.65%)
     
  • HANG SENG

    20,082.43
    +471.59 (+2.40%)
     
  • DAX

    13,682.39
    -18.54 (-0.14%)
     
  • CAC 40

    6,530.70
    +7.26 (+0.11%)
     

Fresenius SE & Co. KGaA: Significantly worsening headwinds at Fresenius Medical Care impact Group net income in FY/22; Fresenius SE & Co. KGaA Group guidance revised

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Fresenius SE & Co. KGaA / Key word(s): Change in Forecast
Fresenius SE & Co. KGaA: Significantly worsening headwinds at Fresenius Medical Care impact Group net income in FY/22; Fresenius SE & Co. KGaA Group guidance revised

27-Jul-2022 / 22:45 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Fresenius SE & Co. KGaA: Significantly worsening headwinds at Fresenius Medical Care impact Group net income in FY/22; Fresenius SE & Co. KGaA Group guidance revised 

Fresenius Medical Care’s financial performance in Q2/22 was significantly impacted by worsened labor shortages and related meaningfully increased wage inflation in the U.S. The further deterioration of the macro-economic environment resulted in accelerated non-wage inflation, particularly higher supply chain costs.
Against this backdrop and growing indications for a persistent unfavorable development of these and other factors, Fresenius Medical Care has revised its outlook for FY/22. 
All other Fresenius Group segments confirm their respective outlook for both revenue and EBIT. 
However, as a consequence of the development at Fresenius Medical Care, and despite all other Fresenius Group segments confirming their respective outlook for both revenue and EBIT, Fresenius now also revises its Group outlook for FY/22. At constant currency, the Company now anticipates Group sales1 to grow in a low-to-mid single-digit percentage range (previously: mid-single digit percentage range) and Group net income2,3 to decline in a low-to-mid single-digit percentage range (previously: increase in a low-single-digit percentage range).
The acquisition of Ivenix and the announced acquisition of the majority stake in mAbxience as well as any further potential acquisitions remain excluded from guidance. 

Preliminary Q2/22 results 
Preliminary Group sales increased by 8% (3% in constant currency) to €10,018 million in Q2/22 versus prior-year quarter. Preliminary net income2,4 declined by 5% (-9% in constant currency5) to €450 million in Q2/22. 

Group medium-term targets
As a result of the updated expectations for FY/22 Fresenius now believes its medium-term net income6 target is no longer achievable. Fresenius had expected Group organic net income6 growth to be at the bottom end of the 5% to 9% compounded annual growth rate (CAGR) range for 2020 to 2023. 
At the same time, Fresenius specifies its Group organic sales growth target to reach the low-end of the targeted 4% to 7% compounded annual growth rate (CAGR) range for 2020 to 2023.


1 FY/21 base: €37,520 million 
2 Net income attributable to shareholders of Fresenius SE & Co. KGaA
3 FY/21 base: €1,867 million, before special items; 2022: before special items
4 Before special items
5 Excluding Ivenix acquisition
6 Net income attributable to shareholders of Fresenius SE & Co. KGaA; before special items

For additional information on the performance indicators used please refer to our website at https://www.fresenius.com/alternative-performance-measures. 


Fresenius SE & Co. KGaA, 
represented by Fresenius Management SE, 
The Management Board

Bad Homburg v.d.H., July 27, 2022


----------------------------------------
Contact:
Markus Georgi
Senior Vice President Investor Relations & Sustainability
T: +49 (0) 6172 608-2485
markus.georgi@fresenius.com
----------------------------------------


End of Note

27-Jul-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Fresenius SE & Co. KGaA

Else-Kröner-Straße 1

61352 Bad Homburg v.d.H.

Germany

Phone:

+49 (0)6172 608-2485

Fax:

+49 (0)6172 608-2488

E-mail:

ir-fre@fresenius.com

Internet:

www.fresenius.com

ISIN:

DE0005785604

WKN:

578560

Indices:

DAX

Listed:

Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Hamburg, Hanover, Stuttgart, Tradegate Exchange; Luxembourg Stock Exchange

EQS News ID:

1407555


 

End of Announcement

DGAP News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting